Filing Details
- Accession Number:
- 0000950170-24-101161
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-27 18:46:50
- Reporting Period:
- 2024-08-23
- Accepted Time:
- 2024-08-27 18:46:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1783328 | Tscan Therapeutics Inc. | TCRX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1741285 | Zoran Zdraveski | C/O Tscan Therapeutics, Inc. 830 Winter Street Waltham MA 02451 | See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Voting Common Stock | Acquisiton | 2024-08-23 | 54,895 | $4.85 | 67,111 | No | 4 | M | Direct | |
| Voting Common Stock | Acquisiton | 2024-08-23 | 25,000 | $3.27 | 92,111 | No | 4 | M | Direct | |
| Voting Common Stock | Acquisiton | 2024-08-23 | 13,125 | $1.81 | 105,236 | No | 4 | M | Direct | |
| Voting Common Stock | Acquisiton | 2024-08-23 | 64,166 | $2.49 | 169,402 | No | 4 | M | Direct | |
| Voting Common Stock | Disposition | 2024-08-23 | 164,686 | $5.78 | 4,716 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Voting Common Stock | Stock Option (Right to Buy) | Disposition | 2024-08-23 | 54,895 | $0.00 | 54,895 | $4.85 |
| Voting Common Stock | Stock Option (Right to Buy) | Disposition | 2024-08-23 | 25,000 | $0.00 | 25,000 | $3.27 |
| Voting Common Stock | Stock Option (Right to Buy) | Disposition | 2024-08-23 | 13,125 | $0.00 | 13,125 | $1.81 |
| Voting Common Stock | Stock Option (Right to Buy) | Disposition | 2024-08-23 | 64,166 | $0.00 | 64,166 | $2.49 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,105 | 2032-01-17 | No | 4 | M | Direct | |
| 25,000 | 2032-07-24 | No | 4 | M | Direct | |
| 21,875 | 2033-02-01 | No | 4 | M | Direct | |
| 365,834 | 2033-06-12 | No | 4 | M | Direct |
Footnotes
- Includes 7,500 shares of Voting Common Stock acquired under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 31, 2022.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.91, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
- The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
- The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
- The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
- 220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.
Billionaire Hedge Funds
